Skip to main content

Market Overview

Veru Hires Advisor To Explore Alternatives For Female Health Business

  • Veru Inc (NASDAQ: VERU) has engaged Morgan Stanley as a financial advisor to pursue strategic alternatives for its legacy Female Healthcare Business.
  • "Furthermore, with the potential for five registration clinical trials in the calendar year 2021, four for oncology indications and one for COVID-19 it is clear that Veru has transformed itself into a premium, late-stage, clinical biopharmaceutical company, so the strategic fit with the FHC Business is not as strong as it once was," said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer.
  • For the fiscal year 2020, the business reported net revenues of $41 million and gross profit of $29 million.
  • Its commercial product is the FC2 Female Condom/ FC2 Internal Condom, the only FDA-approved female condom.
  • Price Action: VERU shares are trading higher by 3% at $12.7 on the last check Monday.

Related Articles (VERU)

View Comments and Join the Discussion!

Posted-In: DivestituresBiotech M&A News Health Care Asset Sales Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at